A multi-pronged approach to raw materials testing can help mitigate the risk of future contamination events.
Catherine Shaffer
Advertisement
Catherine Shaffer is a contributing writer to BioPharm International, cathshaffer@gmail.com.
Articles by Catherine Shaffer
Manufacturing for originator molecules is restricted by regulations, but drug makers can exploit newer technologies for the manufacture of biosimilars.
Advertisement
Latest Updated Articles
Ensuring the Biological Integrity of Raw MaterialsPublished: May 15th 2017 | Updated:
Cost Considerations Drive Lean Technology in BiomanufacturingPublished: May 15th 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2025: The Role of LC–MS in Bioanalysis
2
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
3
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
4
PharmTech Weekly News Roundup – Week of November 3, 2025
5
